PMID- 16609367
OWN - NLM
STAT- MEDLINE
DCOM- 20060727
LR  - 20130524
IS  - 1744-6872 (Print)
IS  - 1744-6872 (Linking)
VI  - 16
IP  - 5
DP  - 2006 May
TI  - A sensitive and rapid alternative to HLA typing as a genetic screening test for 
      abacavir hypersensitivity syndrome.
PG  - 353-7
AB  - BACKGROUND: Abacavir hypersensitivity reaction (ABC HSR) is a potentially 
      life-threatening adverse reaction that affects approximately 8% of patients that 
      initiate this antiretroviral drug. Independent groups have shown a strong 
      predictive association between ABC HSR and HLA-B*5701, indicating that exclusion 
      of HLA-B*5701 positive individuals from abacavir treatment would largely prevent 
      ABC HSR. However, the limited availability and relatively high cost of human 
      leukocyte antigen (HLA) typing represent barriers to the widespread 
      implementation of this pharmacogenetic approach to abacavir prescribing. To 
      facilitate routine screening, we have developed a rapid flow cytometry method for 
      HLA-B57 phenotyping using commercially available B17 monoclonal antibodies. 
      METHODS: Whole blood samples from 84 human immunodeficiency virus (HIV) patients 
      were examined by standard flow cytometry methods, using a two-colour B17-specific 
      immunofluorescence assay in the CD45 lymphocyte population. RESULTS: All eight 
      HLA-B57 individuals examined tested positive, while HLA-B57/58 negative 
      individuals (n=74) tested negative for this flow cytometry test. Two non-HLA-B57 
      individuals showed weak cross-reactivity. CONCLUSION: In our predominantly 
      Caucasian population, B17/CD45 dual staining was sufficient to identify 
      individuals carrying B17 cell surface antigens. This approach, utilizing flow 
      cytometry methods that are widely available in HIV laboratories, therefore offers 
      a sensitive, rapid and cost-effective screening assay prior to abacavir 
      prescription. Following risk stratification with this assay, it would be 
      anticipated that identification of HLA-B*5701 using molecular HLA typing methods 
      would be required in <10% of the screened population.
FAU - Martin, Annalise M
AU  - Martin AM
AD  - Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital 
      and Murdoch University, Perth, Western Australia 6000, Australia.
FAU - Krueger, Romano
AU  - Krueger R
FAU - Almeida, Coral Ann
AU  - Almeida CA
FAU - Nolan, David
AU  - Nolan D
FAU - Phillips, Elizabeth
AU  - Phillips E
FAU - Mallal, Simon
AU  - Mallal S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacogenet Genomics
JT  - Pharmacogenetics and genomics
JID - 101231005
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B57 antigen)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Alleles
MH  - Anti-HIV Agents/*adverse effects/therapeutic use
MH  - Dideoxynucleosides/*adverse effects/therapeutic use
MH  - Drug Hypersensitivity/genetics/*prevention & control
MH  - Flow Cytometry
MH  - *Genetic Testing
MH  - HIV Seropositivity
MH  - HLA-B Antigens/genetics
MH  - Histocompatibility Testing/*methods
MH  - Humans
MH  - Sensitivity and Specificity
EDAT- 2006/04/13 09:00
MHDA- 2006/07/28 09:00
CRDT- 2006/04/13 09:00
PHST- 2006/04/13 09:00 [pubmed]
PHST- 2006/07/28 09:00 [medline]
PHST- 2006/04/13 09:00 [entrez]
AID - 01213011-200605000-00007 [pii]
AID - 10.1097/01.fpc.0000197468.16126.cd [doi]
PST - ppublish
SO  - Pharmacogenet Genomics. 2006 May;16(5):353-7. doi: 
      10.1097/01.fpc.0000197468.16126.cd.